Figure 2

Overview of gene alterations in untreated, operable, non-metastatic HNSCC patients (N = 56) (A). Prognostic value of CDKN2A/B co-deletion on overall survival (B), and progression-free survival (C). Prognostic value of CCND1 amplification on progression-free survival (D).